PRESS RELEASE published on 05/31/2024 at 07:05, 2 years 3 months ago Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO. Dupixent deviendrait la première thérapie ciblée pour la BPCO en Europe Traitement Approbation BPCO Dupixent CHMP
PRESS RELEASE published on 05/31/2024 at 07:05, 2 years 3 months ago Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU Dupixent CHMP EU Approval COPD Treatment Type 2 Inflammation
BRIEF published on 05/30/2024 at 15:06, 2 years 3 months ago Sanofi finalise l’acquisition d’Inhibrx, Inc. Acquisition Sanofi Maladies Rares Inhibrx SAR447537
BRIEF published on 05/30/2024 at 15:06, 2 years 3 months ago Sanofi Completes Acquisition of Inhibrx, Inc. Acquisition Sanofi Rare Diseases Inhibrx SAR447537
PRESS RELEASE published on 05/30/2024 at 15:01, 2 years 3 months ago Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc. Sanofi finalise l’acquisition d’Inhibrx, Inc. ajoutant le SAR447537 à son portefeuille pour le développement de médicaments différenciés dans les maladies rares Acquisition Sanofi Maladies Rares Inhibrx SAR447537
PRESS RELEASE published on 05/30/2024 at 15:01, 2 years 3 months ago Press Release: Sanofi completes acquisition of Inhibrx, Inc. Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB Acquisition Nasdaq Sanofi Inhibrx SAR447537
BRIEF published on 05/27/2024 at 07:05, 2 years 3 months ago La FDA accorde un examen prioritaire au Sarclisa pour le traitement du myélome multiple FDA Sanofi Myélome Multiple Sarclisa Chimiothérapie
BRIEF published on 05/27/2024 at 07:05, 2 years 3 months ago FDA Grants Priority Review to Sarclisa for Treatment of Multiple Myeloma FDA Sanofi Multiple Myeloma Sarclisa Chemotherapy
PRESS RELEASE published on 05/27/2024 at 07:00, 2 years 3 months ago Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation La FDA accorde l'examen prioritaire au Sarclisa pour le traitement du myélome multiple nouvellement diagnostiqué non éligibles à une transplantation. Sanofi annonce des résultats positifs de l'étude IMROZ FDA Sanofi Myélome Multiple Sarclisa Examen Prioritaire
BRIEF published on 05/21/2024 at 07:35, 2 years 4 months ago Sanofi, Formation Bio, and OpenAI Announce AI Collaboration Collaboration AI Drug Development Sanofi OpenAI Formation Bio
Published on 09/26/2026 at 01:00, 14 hours 14 minutes ago Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 14 hours 14 minutes ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 16 hours 59 minutes ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 21 hours 44 minutes ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 1 day ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/26/2026 at 07:45, 7 hours 28 minutes ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 15 hours 12 minutes ago Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia
Published on 09/25/2026 at 18:30, 20 hours 44 minutes ago 029 Group SE: Publication of Half-Year Report 2026
Published on 09/25/2026 at 18:00, 21 hours 14 minutes ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.08.26
Published on 09/25/2026 at 17:45, 21 hours 29 minutes ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 21 hours 34 minutes ago Availability of the 2026 half-year financial report